Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)

Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)

The original mechanism of action of myo-inositol and preliminary results available in the literature on its use in IVF suggest its value as adjuvant gonadotropin therapy to reduce the risk of OHSS in PCOS patients.

The aim of the study is to demonstrate that administration of myo-inositol decreases the incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk infertile with PCOS supported in IVF patients.

Inclusion Criteria:

• Patients PCOS (Rotterdam ESHRE / ASRM criteria)

Combination of at least two of the following three criteria:

• Cycle disorder
• Clinical hyperandrogenism and / or biological
• Account antral follicles> 24
• Age ≤ 18 ≤ 38 years
• BMI <35 kg / m²
• Able to understand the protocol and signed informed consent

Exclusion Criteria:

• Patients not having the Rotterdam criteria
• Patients> 38 years and / or BMI> 35 kg / m²
• Woman enjoying a measure of legal protection
• Hypersensitivity to any component of the Inofolic (myo-inositol, soy, folic acid, glycerol, gelatin, coloring E171)
• Participation in another interventional biomedical research with treatment administered may disrupt ovarian stimulation